ClinicalTrials.gg
RecruitingNCT07673120Updated Sep 28, 2026

A Study to Assess Safety, Tolerability, and How Single and Multiple Injections or Infusions of ABBV-313 Affects the Body of Adult Participants

A Phase 1 interventional study of ABBV-313 and Placebo in Healthy Volunteers, sponsored by AbbVie. Recruiting at 2 sites in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by AbbVie · Phase 1, Interventional, and Basic science

From the registry’s dates

  • Started Jun 2026; still recruiting 4 months later.
Updated Sep 28, 20261 site addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The objective of this study is to assess the safety, tolerability, pharmacokinetics, and immunogenicity of single and multiple doses of ABBV-313 in healthy adult participants.

02

Conditions studied

  • Healthy Volunteers

Keywords

  • Healthy Volunteers
  • ABBV-313
03

In context

Lead sponsor

AbbVie is the lead sponsor of 977 studies on the registry; 136 are open to participants now.

Of its 359 completed or terminated interventional studies of FDA-regulated products, 215 (60%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • is >= 18.0 to \<= 29.9 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
  • A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead .

Exclusion criteria

Exclusion Criteria:

  • History of any sensitivity or allergy to any medication or food.
  • History of any clinically significant illness/infection/major febrile illness, hospitalization, or any surgical procedure within 30 days prior to the first dose of study treatment.
  • Participant has prior exposure to ABBV-313 within the past 300 days.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
64 participants (estimated)

Study arms

  • Experimental
    Part 1, Group 1: ABBV-313 or Placebo

    Participants will receive a single dose of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 1, Group 2: ABBV-313 or Placebo

    Participants will receive a single dose of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 1, Group 3: ABBV-313 or Placebo

    Participants will receive a single dose of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 1, Group 4: ABBV-313 or Placebo

    Participants will receive a single dose of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 1, Group 5: ABBV-313 or Placebo

    Participants will receive a single dose of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 1, Group 6: ABBV-313 or Placebo

    Participants will receive a single dose of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 2, Group 7: ABBV-313 or Placebo

    Participants will receive multiple doses of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

  • Experimental
    Part 2, Group 8: ABBV-313 or Placebo

    Participants will receive multiple doses of ABBV-313 or Placebo

    Drug: ABBV-313 · Drug: Placebo

Interventions

  • DrugABBV-313

    Injection

  • DrugPlacebo

    Injection

  • DrugABBV-313

    Infusion

  • DrugPlacebo

    Infusion

06

What researchers measure

Primary outcomes

  1. Number of Participants with Adverse Events (AEs)

    An AE is defined as any untoward medical occurrence in a patient or clinical investigation in which a participant is administered a pharmaceutical product which does not necessarily have a causal relationship with this treatment.

    Time frame: Up to Approximately Day 329

  2. Maximum Observed Plasma Concentration (Cmax) of ABBV-313

    Cmax of ABBV-313.

    Time frame: Up to Approximately Day 329

  3. Time to Cmax (Tmax) of ABBV-313

    Tmax of ABBV-313.

    Time frame: Up to Approximately Day 329

  4. Terminal Phase Elimination Rate Constant (Beta) of ABBV-313

    Beta of ABBV-313.

    Time frame: Up to Approximately Day 329

  5. Terminal Phase Elimination Half-Life (t1/2) of ABBV-313

    t1/2 of ABBV-313.

    Time frame: Up to Approximately Day 329

  6. Area Under the Plasma Concentration-Time Curve (AUC) From Time 0 to the Time of the Last Measurable Concentration (AUCt) of ABBV-313

    AUCt of ABBV-313.

    Time frame: Up to Approximately Day 329

07

Study locations

2 of 2 sites recruiting
  • CenExel Act- Anaheim Clinical Trials /ID# 285208
    Anaheim, California 92801, United States
    Recruiting
  • Acpru /Id# 283495
    Grayslake, Illinois 60030, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2026 (actual). Primary completion is estimated for Feb 2028, 20 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 23, 2026
First posted
Jun 29, 2026
StartActual
Jun 24, 2026
Primary completionEst.
Feb 2028
CompletionEst.
Feb 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added
Show site
  • CenExel Act- Anaheim Clinical Trials /ID# 285208 · Anaheim, United States
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    1 site added
    Show site
    • CenExel Act- Anaheim Clinical Trials /ID# 285208 · Anaheim, United States
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07673120
Lead sponsor
AbbVie
Responsible party
Sponsor
First posted
Jun 29, 2026
Start date
Jun 24, 2026
Primary completion
Feb 2028 (estimated)
Completion
Feb 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

ABBVIE CALL CENTER
Contact
abbvieclinicaltrials@abbvie.com
844-663-3742
ABBVIE INC.
study director · AbbVie

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion